Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 10/20 | 0.36 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.35 |
| ▸ | TERT | O14746 | 1/20 | 0.34 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.34 |
| ▸ | PRMT3 | O60678 | 1/20 | 0.34 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.34 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.33 |
| ▸ | TCF7L2 | Q9NQB0 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.33 |
| ▸ | KIT | P10721 | 1/20 | 0.33 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.33 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.33 |
| ▸ | HTR4 | Q13639 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14228569 | 0.96 | HRH3 (0.38) | HRH3CSNK2A1KCNH2ADRA2AADRA2B | |
| SCHEMBL14228570 | 0.95 | HRH3 (0.39) | HRH3CSNK2A1KCNH2ADRA2AADRA2B | |
| SCHEMBL12161248 | 0.93 | P2RY12 (0.39) | HRH3TERTP2RY12KCNH2ADRA2A | |
| SCHEMBL9922925 | 0.92 | P2RY12 (0.39) | HRH3TERTP2RY12KCNH2ADRA2A | |
| SCHEMBL14228346 | 0.89 | P2RY12 (0.39) | HRH3TERTP2RY12KCNH2 | |
| SCHEMBL9922918 | 0.89 | P2RY12 (0.37) | HRH3P2RY12KCNH2ADRA2AADRA2B | |
| SCHEMBL9923192 | 0.88 | HRH3 (0.36) | HRH3MCHR1TERTP2RY12CTNNB1 | |
| SCHEMBL9922709 | 0.88 | P2RY12 (0.37) | HRH3P2RY12KCNH2ADRA2AADRA2B | |
| SCHEMBL12177212 | 0.88 | P2RY12 (0.34) | PRMT3P2RY12KIT | |
| SCHEMBL9922926 | 0.86 | KMT2A (0.42) | CSNK2A1P2RY12KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120149688-A1 | PLATELET ADP RECEPTOR INHIBITORS | PORTOLA PHARMACEUTICALS, INC. (US) | 2012-06-14 | — | — | US | disclosed |
| US-8067428-B2 | Platelet ADP receptor inhibitors | PORTOLA PHARMACEUTICALS, INC. (US) | 2011-11-29 | — | — | US | disclosed |
| US-20100234350-A1 | PLATELET ADP RECEPTOR INHIBITORS | PORTOLA PHARMACEUTICALS, INC. (US) | 2010-09-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100234350-A1 | PLATELET ADP RECEPTOR INHIBITORS | TBXA2R, GP6, P2RY6 | HRH3 1906/4885MCHR1 3938/4885TERT 2603/4885 |
| US-20120149688-A1 | PLATELET ADP RECEPTOR INHIBITORS | TBXA2R, GP6, P2RY6 | HRH3 1858/4885MCHR1 3907/4885TERT 2585/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.